Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACI Formulations's EBIT per Share for the
three
months ended in Mar. 2026 was BDT3.57.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was BDT15.05.
During the past 12 months, the average EBIT per Share Growth Rate of ACI Formulations was -15.90% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 17.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 14.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 6.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for ACI Formulations's EBIT per Share or its related term are showing as below:
DHA:ACIFORMULA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -10.4 Med: 7.9 Max: 25.8
Current: 17.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of ACI Formulations was 25.80% per year. The lowest was -10.40% per year. And the median was 7.90% per year.
DHA:ACIFORMULA's 3-Year EBIT Growth Rate is ranked better than 83.72% of 215
companies
in the Agriculture industry
Industry Median: -4.6
vs DHA:ACIFORMULA: 17.20
ACI Formulations (DHA:ACIFORMULA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
ACI Formulations EBIT per Share Related Terms
ACI Formulations EBIT per Share Historical Data
* Premium members only.
The historical data trend for ACI Formulations's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT15.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACI Formulations (DHA:ACIFORMULA) has a EBIT per Share of BDT15.05 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ACI Formulations and its competitors. According to the industry distribution chart, ACI Formulations ranks #35 out of 215 companies in the Agriculture industry, placing it in the top 16.3%.
Is ACI Formulations' EBIT per Share too high?
ACI Formulations' current EBIT per Share is BDT15.05. Based on the distribution chart, ACI Formulations ranks #35 out of 215 companies in the Agriculture industry, which is in the top quartile — a strong position relative to peers. Overall, ACI Formulations has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACI Formulations' EBIT per Share compare to CTVA and CF?
According to the Agriculture industry distribution chart, ACI Formulations ranks #35 out of 215 companies for EBIT per Share. This places ACI Formulations in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for an Agriculture company?
A good EBIT per Share depends on the Agriculture industry context. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ACI Formulations and its competitors. ACI Formulations's current EBIT per Share is BDT15.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACI Formulations stock overvalued right now?
Based on GuruFocus' analysis, ACI Formulations (DHA:ACIFORMULA) is currently considered Fairly Valued. The stock's GF Value™ is BDT150.73, compared to a current price of BDT152.70 — trading 1.3% above its estimated fair value. The current EBIT per Share is BDT15.05. ACI Formulations' overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For ACI Formulations (DHA:ACIFORMULA), the current EBIT per Share is BDT15.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACI Formulations (DHA:ACIFORMULA) Overvalued in 2026?
Based on GuruFocus' analysis, ACI Formulations stock appears to be overvalued.
The current stock price of BDT152.70 is trading 1.3% above its estimated GF Value™ of BDT150.73.
GuruFocus considers ACI Formulations to be Fairly Valued.
Key valuation signals for DHA:ACIFORMULA:
EBIT per Share: BDT15.05
GF Value™: BDT150.73 vs. price of BDT152.70 (1.3% above fair value)
No single metric tells the full story. See the DHA:ACIFORMULA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACI Formulations PLC is engaged in the manufacturing and marketing of several agrochemical and consumer products. The company offers a complete range of cost-effective solutions for farmers through formulating and marketing insecticides, herbicides, fungicides, miticides, etc. Its businesses are Pharmaceuticals, Salt, Skincare & Antiseptics, Kitchen Care, Fabric Care, Surface Care, Herbal Care, Lavatory Care, and Others. The group's reportable segments are Crop Care and Public Health (CC & PH), which include manufacturing and selling crop care and public health products; Mosquito coil (M. Coil) includes manufacturing and selling mosquito coil products; Aerosol provides manufacturing and selling aerosol and air freshener products; and Paint covers manufacture and sell paint products.
91GF Score
Get the complete analysis for DHA:ACIFORMULA
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACIFORMULA has been successfully added to your 
